- Home
- AKBA vs VTLE Comparison
AKBA vs VTLE Comparison
Compare AKBA & VTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- VTLE
- Stock Information
- Founded
- AKBA 2007
- VTLE 2006
- Country
- AKBA United States
- VTLE United States
- Employees
- AKBA N/A
- VTLE N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- VTLE
- Sector
- AKBA Health Care
- VTLE
- Exchange
- AKBA Nasdaq
- VTLE Nasdaq
- Market Cap
- AKBA 669.7M
- VTLE 591.0M
- IPO Year
- AKBA 2014
- VTLE 2011
- Fundamental
- Price
- AKBA $3.69
- VTLE $16.50
- Analyst Decision
- AKBA Strong Buy
- VTLE Hold
- Analyst Count
- AKBA 5
- VTLE 11
- Target Price
- AKBA $6.90
- VTLE $27.11
- AVG Volume (30 Days)
- AKBA 6.0M
- VTLE 1.3M
- Earning Date
- AKBA 05-08-2025
- VTLE 05-12-2025
- Dividend Yield
- AKBA N/A
- VTLE N/A
- EPS Growth
- AKBA N/A
- VTLE N/A
- EPS
- AKBA N/A
- VTLE N/A
- Revenue
- AKBA $184,909,000.00
- VTLE $1,982,155,000.00
- Revenue This Year
- AKBA $23.32
- VTLE $4.24
- Revenue Next Year
- AKBA $49.90
- VTLE N/A
- P/E Ratio
- AKBA N/A
- VTLE N/A
- Revenue Growth
- AKBA N/A
- VTLE 16.77
- 52 Week Low
- AKBA $0.80
- VTLE $12.30
- 52 Week High
- AKBA $3.73
- VTLE $47.80
- Technical
- Relative Strength Index (RSI)
- AKBA 83.69
- VTLE 53.21
- Support Level
- AKBA $2.76
- VTLE $15.04
- Resistance Level
- AKBA $3.73
- VTLE $17.92
- Average True Range (ATR)
- AKBA 0.18
- VTLE 0.91
- MACD
- AKBA 0.07
- VTLE 0.21
- Stochastic Oscillator
- AKBA 96.67
- VTLE 63.68
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.